U.S. Markets closed

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2505-0.0213 (-7.84%)
At close: 3:58PM EDT

Mydecine Innovations Group Inc.

789 West Pender Street
Suite 810
Vancouver, BC V6C 1H2

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. David Joshua BartchCo-Founder, CEO, Pres & Chairman121.23kN/A1987
Mr. Robert RoscowCo-Founder, Chief Scientific Officer & Director137.99kN/AN/A
Mr. Damon MichaelsCOO, Co-Founder & Director159.31kN/AN/A
Mr. Dean DittoChief Financial OfficerN/AN/AN/A
Mr. Sanford M. SteinGen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Jim GunningChief Marketing OfficerN/AN/AN/A
Dr. Rakesh Jetly FRCPC, M.D.Chief Medical OfficerN/AN/AN/A
Mr. Michel RudolphiePres of the European OperationsN/AN/AN/A
Mr. William CookInterim CEO & Technical Director of Mindleap Health Inc.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post traumatic stress disorder, and frontline workers; and digital health solutions, such as digital therapeutics and quantified mental health solutions. The company also engages in the drug discovery and delivery activities. In addition, it is involved in the operation of real estate and farm properties in North America. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. is headquartered in Vancouver, Canada.

Corporate Governance

Mydecine Innovations Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.